Potential Benefit of Probiotic E. Coli Nissle in Term Neonates
Klinische Pädiatrie · 01.07.2023 · 235 (04) · 213-220
DOI: 10.1055/a-1970-4340 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Klinische Pädiatrie, erschienen am 01.07.2023. Verfasst von Dirk Olbertz und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neonatology, Klinikum Südstadt Rostock, Rostock, Germany. Hauptthemen laut MEDLINE: Escherichia coli, Probiotics. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Probiotics are often viewed as an immunity enhancing agent. The objective of this study was to investigate whether oral administration of Escherichia coli Nissle 1917 reduces the number of infections, their duration, and severity in the first 24 months after parturition in healthy neonates. Subjects and methods This prospective, confirmatory, randomised, double-blind, placebo-controlled study enrolled 567 healthy neonates from four German and two Polish sites. Neonates received 10e8 viable E. coli Nissle (n=283) or placebo (n=284) daily in the first week and every second day in week 2 and 3. After 6 and 12 months, the subjects received additional instillations on ten subsequent days. The overall efficacy was assessed by the number of infections per observation period.
Results
Incidence rates of infection, infection duration and severity showed no statistically significant difference between groups after 24 months. Post-hoc analyses, however, revealed a short-term benefit of E. coli Nissle four weeks after treatment start which became less pronounced after eight weeks. E. coli Nissle was safe and well tolerated.
Conclusions
A long-term effect after colonising the healthy neonate´s gut with E. coli Nissle to protect against infections could not be shown. Additional studies are needed to confirm a transitory, yet clinically significant role of probiotics in the first four weeks after parturition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Neonatology, Klinikum Südstadt Rostock, Rostock, Germany.
- Section of Neonatology and Neonatal Intensive Care, Department of Pediatrics, Jena University Hospital, Jena, Germany.
- Pediatrics, Children's Hospital St. Elisabeth and St. Barbara, Halle/Saale, Germany.
- Department of Pediatrics, Klinikum Westbrandenburg, Potsdam, Germany.
- Department of Neonatology, University Clinical Centre of Warsaw Medical University, Warsaw, Poland.
- Department of Neonatology, Nicolaus Copernicus University in Toruń Ludwik Rydygier Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland.
ORCID-Profile: Thomas Erler
Zitieren
APA
Olbertz, D., Proquitté, H., Patzer, L., Erler, T., Mikolajczak, A., Sadowska-Krawczenko, I., Wolff, C., & Radke, M. (2023). Potential Benefit of Probiotic E. Coli Nissle in Term Neonates. Klinische Pädiatrie, 235(04), 213-220. https://doi.org/10.1055/a-1970-4340
Vancouver
Olbertz D, Proquitté H, Patzer L, Erler T, Mikolajczak A, Sadowska-Krawczenko I, et al. Potential Benefit of Probiotic E. Coli Nissle in Term Neonates. Klinische Pädiatrie. 2023;235(04):213-220. doi:10.1055/a-1970-4340
BibTeX
@article{Olbertz2023,
author = {Olbertz, Dirk and Proquitté, Hans and Patzer, Ludwig and Erler, Thomas and Mikolajczak, Alexsandra and Sadowska-Krawczenko, Iwona and Wolff, Corinna and Radke, Michael},
title = {Potential Benefit of Probiotic E. Coli Nissle in Term Neonates},
journal = {Klinische Pädiatrie},
year = {2023},
volume = {235},
number = {04},
pages = {213--220},
doi = {10.1055/a-1970-4340}
}
EUVIMED